Literature DB >> 12180727

Macrophage migration inhibitory factor gene polymorphism is associated with sarcoidosis in biopsy proven erythema nodosum.

Mahsa M Amoli1, Rachelle P Donn, Wendy Thomson, Ali H Hajeer, Carlos Garcia-Porrua, Mercedes Lueiro, William E R Ollier, Miguel A Gonzalez-Gay.   

Abstract

OBJECTIVE: To assess whether polymorphism of the macrophage migration inhibitory factor (MIF) gene at the position -173 is implicated in the development of sarcoidosis.
METHODS: Twenty-eight patients with biopsy proven erythema nodosum (EN) associated with sarcoidosis, 70 patients with biopsy proven EN related to other etiologies, and 122 healthy matched controls from the Lugo region of Northwest Spain were studied. Patients and controls were genotyped for a single nucleotide polymorphism in the 5'-flanking region at position -173 of the MIF gene, using SNapshot ddNTP primer extension, followed by capillary electrophoresis (ABI 3100).
RESULTS: A significantly increased frequency of the C mutant allele was observed in patients with EN secondary to sarcoidosis compared to controls (p = 0.0016; p(corr) = 0.0032; OR 2.78, 95% CI 1.45, 5.35) and also compared to patients with EN unrelated to sarcoidosis (p = 0.0004; p(corr) = 0.0008; OR 3.72, 95% CI 1.75, 7.87). Patients with EN carrying an MIF 173 C allele were found to have an increased risk of sarcoidosis (57% in EN secondary to sarcoidosis vs 24% in patients with EN related to other etiologies; p = 0.002; p(corr) = 0.004; OR 4.16, 95% CI 1.64, 10.50).
CONCLUSION: This is the first attempt to assess the influence of MIF genetic polymorphism at position -173 in the development of sarcoidosis. The MIF 173 C allele is associated with a significantly increased risk of developing sarcoidosis in patients with EN.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12180727

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  13 in total

1.  Macrophage migration inhibitory factor and its genetic association with arthritis: a work in progress.

Authors:  Timothy R D J Radstake; Richard Bucala
Journal:  Curr Rheumatol Rep       Date:  2007-10       Impact factor: 4.592

2.  Role of Macrophage Migration Inhibitory Factor in Granulomatosis With Polyangiitis.

Authors:  Antoine G Sreih; Rana Ezzedine; Lin Leng; Juan Fan; Jie Yao; Duncan Reid; Marta Piecychna; Simon Carette; David Cuthbertson; Paul Dellaripa; Gary S Hoffman; Nader A Khalidi; Curry L Koening; Carol A Langford; Alfred Mahr; Carol A McAlear; Kathleen Maksimowicz-Mckinnon; Paul A Monach; Philip Seo; Ulrich Specks; E William St Clair; John H Stone; Steven R Ytterberg; Jeffrey Edberg; Peter A Merkel; Richard Bucala
Journal:  Arthritis Rheumatol       Date:  2018-10-22       Impact factor: 10.995

3.  Dual effect of the macrophage migration inhibitory factor gene on the development and severity of human systemic lupus erythematosus.

Authors:  Antoine Sreih; Rana Ezzeddine; Lin Leng; Avery LaChance; Geraldine Yu; Yuka Mizue; Lakshman Subrahmanyan; Bernardo A Pons-Estel; Anna-Karin Abelson; Iva Gunnarsson; Elisabet Svenungsson; Joshua Cavett; Stuart Glenn; Lin Zhang; Ruth Montgomery; Andras Perl; Jane Salmon; Marta E Alarcón-Riquelme; John B Harley; Richard Bucala
Journal:  Arthritis Rheum       Date:  2011-12

Review 4.  Macrophage migration inhibitory factor (MIF) as a therapeutic target for rheumatoid arthritis and systemic lupus erythematosus.

Authors:  Joshua B Bilsborrow; Edward Doherty; Pathricia V Tilstam; Richard Bucala
Journal:  Expert Opin Ther Targets       Date:  2019-08-20       Impact factor: 6.902

5.  Evaluation of MIF -173 G/C Polymorphism in Turkish Patients with Ankylosing Spondylitis.

Authors:  Çevik Gürel; Ahmet İnanır; Ayşe Feyda Nursal; Akın Tekcan; Aydın Rüstemoğlu; Serbülent Yigit
Journal:  Balkan Med J       Date:  2016-11-01       Impact factor: 2.021

6.  Association of MIF gene polymorphisms with pemphigus vulgaris: a case-control study with comprehensive review of the literature.

Authors:  Parikshaa Gupta; Neha Joshi; Shradha Uprety; Sunil Dogra; Dipankar De; Sanjeev Handa; Ranjana Walker Minz; Sukhvinder Singh; Seema Chhabra
Journal:  Int J Clin Exp Pathol       Date:  2021-11-15

7.  Role of migratory inhibition factor in age-related susceptibility to radiation lung injury via NF-E2-related factor-2 and antioxidant regulation.

Authors:  Biji Mathew; Jeffrey R Jacobson; Jessica H Siegler; Jaideep Moitra; Michael Blasco; Lishi Xie; Crystal Unzueta; Tong Zhou; Carrie Evenoski; Mohammed Al-Sakka; Rajesh Sharma; Ben Huey; Aydogan Bulent; Brett Smith; Sundararajan Jayaraman; Narsa M Reddy; Shekhar P Reddy; Günter Fingerle-Rowson; Richard Bucala; Steven M Dudek; Viswanathan Natarajan; Ralph R Weichselbaum; Joe G N Garcia
Journal:  Am J Respir Cell Mol Biol       Date:  2013-08       Impact factor: 6.914

Review 8.  Macrophage migration inhibitory factor (MIF): a key player in protozoan infections.

Authors:  Juan de Dios Rosado; Miriam Rodriguez-Sosa
Journal:  Int J Biol Sci       Date:  2011-10-25       Impact factor: 6.580

9.  The association between the migration inhibitory factor -173G/C polymorphism and cancer risk: a meta-analysis.

Authors:  Xiao Zhang; Wenhao Weng; Wen Xu; Yulan Wang; Wenjun Yu; Xun Tang; Lifang Ma; Qiuhui Pan; Jiayi Wang; Fenyong Sun
Journal:  Onco Targets Ther       Date:  2015-03-10       Impact factor: 4.147

10.  A MIF haplotype is associated with the outcome of patients with severe sepsis: a case control study.

Authors:  Lutz E Lehmann; Malte Book; Wolfgang Hartmann; Stefan U Weber; Jens-Christian Schewe; Sven Klaschik; Andreas Hoeft; Frank Stüber
Journal:  J Transl Med       Date:  2009-11-26       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.